Reuters: Trouble mounts for Sanofi dengue vaccine over safety concerns
“The World Health Organization said on Monday it hopes to review safety data on Sanofi’s dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases…” (Berkrot/Serapio, 12/4).

Reuters: Severe dengue vaccine risk in uninfected ‘2 in a 1,000’: Sanofi
“French drugmaker Sanofi said on Tuesday the risk of severe dengue occurring in previously uninfected people given its Dengvaxia dengue vaccine was around two in 1,000 and these individuals recovered with treatment…” (Hirschler, 12/5).

Reuters: WHO reviewing data on Sanofi dengue vaccine, urges limited use
“…WHO spokesman Christian Lindmeier, referring to the WHO’s SAGE (Strategic Advisory Group of Experts) and its separate Global Advisory Committee on Vaccine Safety, told Reuters that the experts want to ‘meet before the end of the year'” (Nebehay, 12/4).

Reuters: Brazil recommends restrictions on Sanofi dengue vaccine
“The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases…” (Boadle/Brooks, 12/4).

Wall Street Journal: Philippines Suspends Troubled Dengue Drug After More Than 730,000 Immunized
“…On Monday, … the government said it had a record of all the children who had received the vaccine and would monitor them for five years for signs of the disease. It played down the impact of the new findings, noting that the threat of a severe dengue contraction was a risk only for those who had not had dengue before, but had been given the vaccine…” (Watts et al., 12/4).